Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 monoclonal antibody + chidamide ± DLI after allo-HSCT in relapsed myeloid malignancies
ChiCTR2500109662Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody and tucidinostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibodytucidinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500109662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109662.